Highly Active Anti-Retroviral Therapy
Reduces progression to<unk>  and transmission risk
CDC Guidelines =  all<unk> + individuals should be started on HAART, regardless of CD4 count or viral load
Typical first line regimens include a reverse transcriptase inhibitor (NRTI) and an integrase inhibitor
tenofovir/emtricitabine (Truvada) PLUS raltegravir (Isentress)
tenofovir/emtricitabine (Truvada) PLUS dolutegravir (Tivicay)
tenofovir/emtricitabine (Truvada) PLUS raltegravir (Isentress)
tenofovir/emtricitabine (Truvada) PLUS dolutegravir (Tivicay)
HIV - AIDS 
HIV neurologic complications
COVID-19: Management of recovered patients
Toxoplasmosis
COVID-19: Example hospital protocols
Cryptococcosis
AIDS Dementia
Hepatitis D